Snake cathelicidin fragment without antimicrobial activity reverses antibiotic resistance by trapping drugs inside bacteria | Research

The takeaway

FP-CATH9, a 9-residue snake cathelicidin fragment with no antibacterial activity, reverses minocycline resistance in MDR gram-negative bacteria by inhibiting efflux pumps to increase intracellular drug accumulation, with 80% larval survival in vivo.

Non-antibiotic peptide reverses resistance
A 9-amino acid snake cathelicidin fragment with zero antibacterial activity reversed minocycline resistance in 4 MDR gram-negative species by trapping the drug inside bacteria

What the researchers found

FP-CATH9: 9 amino acids, no antibacterial activity alone. Reverses minocycline resistance in MDR gram-negative bacteria (E. coli, K. pneumoniae, A. baumannii, P. aeruginosa). Mechanism: inhibits efflux → ↑intracellular minocycline. Low hemolysis + cytotoxicity. In vivo: 80% larval survival with combination.

Why it matters

Antibiotic resistance is a global crisis. A non-toxic peptide that makes existing antibiotics effective again—without having antimicrobial activity itself—is a novel approach to the resistance problem.

How the study worked

Double-dilution dose-response. Checkerboard synergy (FICI). Ethidium bromide efflux assay. Hemolysis and RAW264.7 cytotoxicity. Galleria mellonella MDR K. pneumoniae infection model.

What this study cannot tell us

Larval model only. Minocycline-specific—unknown if it works with other antibiotics. Mechanism of efflux inhibition not fully characterized. Manufacturing of specific peptide fragments needs evaluation.

How to read the evidence

Comprehensive preclinical study with mechanism, spectrum, safety, and in vivo validation. Strong proof of concept.

When this study was published

Published in 2025.

The bigger picture

This reveals a new role for antimicrobial peptide fragments: not as direct killers but as antibiotic adjuvants that reverse resistance. Many "inactive" peptide fragments may have unrecognized synergistic potential.

Questions still open

Would FP-CATH9 reverse resistance to other tetracyclines or antibiotic classes?
What is the specific efflux pump target?
Can FP-CATH9 be administered systemically in mammals?

Common questions

How can a peptide with no antibiotic activity fight resistance?

FP-CATH9 does not kill bacteria on its own—instead, it blocks the bacterial "pumps" that expel antibiotics like minocycline. By trapping the antibiotic inside bacteria, the drug can reach effective concentrations again. This is like plugging the drain in a bathtub so the water level (drug concentration) rises.

Why is this important for drug-resistant infections?

Rather than developing entirely new antibiotics (expensive and slow), this approach makes existing antibiotics work again against resistant bacteria. It was effective against 4 major resistant gram-negative species and protected 80% of infected organisms in vivo. This could be a faster path to treating resistant infections.

Read the original research

A novel function of short cationic peptide FP-CATH9 without antimicrobial activity reverses resistance to minocycline in common multidrug-resistant gram-negative bacteria.

Microbiology spectrum, 13(4), e0290824

View on PubMed ↗Publisher’s paper ↗

Citation

Tang, Yingqi; Liu, Jiye; Yan, Jiani; Xie, Zhixiong; Zhong, Lipeng. (2025). A novel function of short cationic peptide FP-CATH9 without antimicrobial activity reverses resistance to minocycline in common multidrug-resistant gram-negative bacteria.. Microbiology spectrum, 13(4), e0290824. https://doi.org/10.1128/spectrum.02908-24